Knights of Columbus Asset Advisors’s Krystal Biotech KRYS Stock Holding History

Knights of Columbus Asset Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.55M	Buy	+4,175	New	+$1.25M	0.08%	245

Other funds holding KRYS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Knights of Columbus Asset Advisors's KRYS Position: Q2 2026 in Review

Knights of Columbus Asset Advisors opened a new position in Krystal Biotech (KRYS) in Q2 2026: 4,175 shares worth $1.55M. The stake represents 0.08% of the portfolio and ranks #245 among its holdings.

191 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Knights of Columbus Asset Advisors held 4,175 shares of Krystal Biotech worth $1.55M as of Q2 2026.
Krystal Biotech was a new Knights of Columbus Asset Advisors position in Q2 2026.
Krystal Biotech made up 0.08% of Knights of Columbus Asset Advisors's portfolio in Q2 2026, its #245 holding.
191 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Knights of Columbus Asset Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.